Chanson International’s “Songkang Meal” Nasogastric Nutrition Formula Approved for Use in China
Chanson International Holding (NASDAQ: CHSN) has received approval in China for its first Food for Special Medical Purpose (FSMP) product, the "Songkang Meal" nasogastric nutrition formula series. The product, specifically developed for patients with chronic conditions like diabetes and kidney disease, features a low-glycemic index carbohydrate and plant-based protein blend, incorporating local Xinjiang ingredients.
Initial market reception has been positive, with over 1,000 patients using the product in its first month. The company leverages its existing retail network to ensure 48-hour delivery to hospital partners. Building on this launch, Chanson plans to introduce five new nutrition products by 2026 and aims to expand nationwide from its initial Xinjiang market.
Chanson International Holding (NASDAQ: CHSN) ha ottenuto l'approvazione in Cina per il suo primo prodotto Alimentare per Scopi Medici Speciali (FSMP), la serie di formule nutrizionali nasogastriche "Songkang Meal". Il prodotto, sviluppato appositamente per pazienti con condizioni croniche come diabete e malattie renali, presenta un carboidrato a basso indice glicemico e una miscela di proteine vegetali, incorporando ingredienti locali dello Xinjiang.
La risposta iniziale del mercato è stata positiva, con oltre 1.000 pazienti che hanno utilizzato il prodotto nel primo mese. L'azienda sfrutta la sua rete di vendita al dettaglio esistente per garantire la consegna in 48 ore ai partner ospedalieri. Sulla base di questo lancio, Chanson prevede di introdurre cinque nuovi prodotti nutrizionali entro il 2026 e di espandersi a livello nazionale partendo dal mercato iniziale dello Xinjiang.
Chanson International Holding (NASDAQ: CHSN) ha recibido la aprobación en China para su primer producto de Alimentos para Fines Médicos Especiales (FSMP), la serie de fórmulas nutricionales nasogástricas "Songkang Meal". El producto, desarrollado específicamente para pacientes con condiciones crónicas como diabetes y enfermedad renal, cuenta con un carbohidrato de bajo índice glucémico y una mezcla de proteínas vegetales, incorporando ingredientes locales de Xinjiang.
La recepción inicial del mercado ha sido positiva, con más de 1,000 pacientes utilizando el producto en su primer mes. La compañía aprovecha su red de venta minorista existente para garantizar la entrega en 48 horas a sus socios hospitalarios. Basándose en este lanzamiento, Chanson planea introducir cinco nuevos productos nutricionales para 2026 y tiene como objetivo expandirse a nivel nacional desde su mercado inicial en Xinjiang.
Chanson International Holding (NASDAQ: CHSN)은 중국에서 첫 번째 특수의료용도 식품(FSMP) 제품인 "Songkang Meal" 비위관 영양 포뮬러 시리즈에 대한 승인을 받았습니다. 이 제품은 당뇨병 및 신장 질환과 같은 만성 질환 환자를 위해 특별히 개발되었으며, 저혈당 지수 탄수화물과 식물성 단백질 혼합물을 특징으로 하며, 신장 지역의 현지 재료를 포함하고 있습니다.
초기 시장 반응은 긍정적이었으며, 첫 달에 1,000명 이상의 환자가 제품을 사용했습니다. 회사는 기존 소매 네트워크를 활용하여 병원 파트너에게 48시간 내 배송을 보장합니다. 이번 출시를 기반으로 Chanson은 2026년까지 5개의 신규 영양 제품을 출시할 계획이며, 초기 신장 시장에서 전국적으로 확장하는 것을 목표로 하고 있습니다.
Chanson International Holding (NASDAQ : CHSN) a obtenu l'approbation en Chine pour son premier produit Aliment destiné à des fins médicales spéciales (FSMP), la série de formules nutritionnelles nasogastriques "Songkang Meal". Ce produit, spécialement conçu pour les patients souffrant de maladies chroniques telles que le diabète et les maladies rénales, contient un glucide à indice glycémique bas et un mélange de protéines végétales, intégrant des ingrédients locaux du Xinjiang.
Les premières réactions du marché ont été positives, avec plus de 1 000 patients ayant utilisé le produit lors du premier mois. L'entreprise utilise son réseau de distribution existant pour assurer une livraison en 48 heures à ses partenaires hospitaliers. Suite à ce lancement, Chanson prévoit d'introduire cinq nouveaux produits nutritionnels d'ici 2026 et vise une expansion nationale à partir de son marché initial du Xinjiang.
Chanson International Holding (NASDAQ: CHSN) hat in China die Zulassung für sein erstes Lebensmittel für besondere medizinische Zwecke (FSMP) erhalten, die nasogastrische Ernährungsmittel-Serie „Songkang Meal“. Das Produkt, das speziell für Patienten mit chronischen Erkrankungen wie Diabetes und Nierenerkrankungen entwickelt wurde, enthält kohlenhydrate mit niedrigem glykämischen Index und eine pflanzliche Proteinmischung und verwendet lokale Zutaten aus Xinjiang.
Die erste Marktresonanz war positiv, mit über 1.000 Patienten, die das Produkt im ersten Monat nutzten. Das Unternehmen nutzt sein bestehendes Einzelhandelsnetzwerk, um eine Lieferung innerhalb von 48 Stunden an Krankenhauspartner sicherzustellen. Aufbauend auf diesem Start plant Chanson, bis 2026 fünf neue Ernährungsprodukte einzuführen und möchte von seinem anfänglichen Markt in Xinjiang aus landesweit expandieren.
- First FSMP product approval represents expansion into medical nutrition market, creating new revenue streams
- Strong initial adoption with over 1,000 patients using the product in first month
- Efficient 48-hour delivery system to hospitals through existing retail network
- Plans to launch 5 new nutrition products by 2026
- Cost efficiency achieved through local ingredient sourcing and centralized production
- Currently limited to regional market in Xinjiang
- Entering a new market segment with established competitors
- Success dependent on expansion beyond initial regional launch
Insights
Chanson's entry into China's medical nutrition market with an approved FSMP product represents a strategic diversification with promising initial adoption metrics.
Chanson's approval for its "Songkang Meal" nasogastric nutrition formula marks a significant diversification from its core bakery business into the high-growth Food for Special Medical Purpose (FSMP) sector. The product specifically targets patients with chronic conditions like diabetes and kidney disease—representing large and growing patient populations in China due to demographic shifts and lifestyle changes.
The formulation strategy merits attention: utilizing low-glycemic carbohydrates and plant-based proteins addresses specific clinical needs while incorporating regional ingredients like sea buckthorn and chickpeas, which likely enhances local acceptance. This localization approach is particularly astute in China's fragmented healthcare market where regional preferences significantly impact adoption.
Initial performance indicators appear promising with usage by over 1,000 patients in the first month and implementation in multiple Xinjiang hospitals. The reported increase in nutritional compliance rates among 127 patients suggests clinical effectiveness, though more comprehensive outcome data would be needed to fully validate therapeutic benefits.
Chanson's competitive advantage appears to stem from its integrated supply chain—leveraging local ingredient sourcing, production facilities in Xinjiang, and an established retail network enabling 48-hour delivery to hospital partners. This infrastructure addresses the critical challenge of cold-chain distribution in specialized nutrition products, particularly in China's developing western regions.
The company's ambitious plans to launch five additional nutrition products by 2026 signals a committed strategic pivot rather than a one-off product launch. This diversification reduces dependency on their traditional bakery business while potentially opening higher-margin revenue streams in the healthcare sector, where specialized nutrition commands premium pricing.
URUMQI, China, May 13, 2025 (GLOBE NEWSWIRE) -- Chanson International Holding (Nasdaq: CHSN) (the “Company” or “Chanson”), a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States, today announced that its self-developed “Songkang Meal” series of nasogastric nutrition formulas has received official registration approval as a Food for Special Medical Purpose (“FSMP”) in China. The product has been adopted for use in several hospitals in Xinjiang. As the Company’s first FSMP product, “Songkang Meal” represents Chanson’s expansion into the medical nutrition and FSMP market, presenting an opportunity for new revenue streams.
“Songkang Meal” is designed to address market need for FSMP products in Northwest China with its nutritional formulation and localized features. Specifically developed for patients with chronic conditions such as diabetes and kidney disease, the “Songkang Meal” series utilizes a low-glycemic index carbohydrate and plant-based protein blend to balance nutrient density and gastrointestinal tolerance. Its formulation also incorporates ingredients native to Xinjiang, including sea buckthorn and chickpeas. At one hospital in Xinjiang, 127 patients have reportedly used the product, resulting in an increase in nutritional compliance rates. In its first month on the market, “Songkang Meal” was used by over 1,000 patients, achieving satisfactory results. These initial results indicate positive reception in the region.
Chanson’s entry into the FSMP field builds on its experience in food innovation. Drawing from years of experience in bakery production, the Company has applied relevant technologies such as freeze-drying and precision temperature control to the development of stable and high-quality nutrition formulas. By sourcing ingredients locally and centralizing production in Xinjiang, Chanson aims to achieve cost efficiency and raw material traceability. Additionally, the Company’s existing retail network in Xinjiang supports a logistics system capable of delivering FSMP products to hospital partners within 48 hours, addressing a major challenge of cold-chain distribution in the market.
Mr. Gang Li, Chairman of the Board of Directors and Chief Executive Officer of Chanson, commented, “With China’s aging population and rising demand for specialized clinical nutrition, we see an opportunity to extend our food expertise into the FSMP sector. The introduction of ‘Songkang Meal’ in Xinjiang marks a substantial step in this direction. By leveraging our R&D capabilities, local supply chain, and retail network, we are not only addressing an unmet need but also working towards creating a new growth engine for Chanson. We also aim to launch five new nutrition products by 2026, designed to meet the needs of patients across all age groups. With the initial launch of ‘Songkang Meal’ in Xinjiang, we believe we are positioned to scale the model nationwide. We see significant potential in this market and are confident that our integrated capabilities will position us for long-term growth in health-focused food solutions.”
About Chanson International Holding
Founded in 2009, Chanson International Holding is a provider of bakery, seasonal, and beverage products through its chain stores in China and the United States. Headquartered in Urumqi, China, Chanson directly operates stores in Xinjiang, China and New York, United States. Chanson currently manages 63 stores in China, and 3 stores in New York City while selling on digital platforms and third-party online food ordering platforms. Chanson offers not only packaged bakery products but also made-in-store pastries and eat-in services, serving freshly prepared bakery products and extensive beverage products. Chanson aims to make healthy, nutritious, and ready-to-eat food through advanced facilities based on in-depth industry research, while creating a comfortable and distinguishable store environment for customers. Chanson’s dedicated and highly-experienced product development teams constantly create new products that reflect market trends to meet customer demand. For more information, please visit the Company’s website: http://ir.chanson-international.net/.
Forward-Looking Statements
Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions intended to identify forward-looking statements. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the U.S. Securities and Exchange Commission.
For investor and media inquiries, please contact:
Chanson International Holding
Investor Relations Department
Email: IR@chansoninternational.com
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com
FAQ
What is Chanson's (CHSN) Songkang Meal and what was it approved for?
How many patients have used CHSN's Songkang Meal in its first month?
What are Chanson's (CHSN) expansion plans for Songkang Meal?
What unique features does CHSN's Songkang Meal have?
How does Chanson (CHSN) manage the distribution of Songkang Meal?
